| Completed | Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma NCT02337426 | Virginia Commonwealth University | Phase 1 |
| Completed | Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas NCT02186509 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |
| Terminated | 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas NCT02175745 | Erik Mittra | N/A |
| Completed | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Gliom NCT01977677 | Lawrence Recht | Phase 1 / Phase 2 |
| Completed | Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High- NCT02015819 | City of Hope Medical Center | Phase 1 |
| Completed | NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma NCT01894061 | Case Comprehensive Cancer Center | Phase 2 |
| Withdrawn | Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors NCT02194452 | Sue O'Dorisio | N/A |
| Completed | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis NCT01806675 | Sanjiv Sam Gambhir | Phase 1 / Phase 2 |
| Completed | Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma NCT01753713 | Manmeet Ahluwalia, MD | Phase 2 |
| Completed | Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma NCT01730950 | Radiation Therapy Oncology Group | Phase 2 |
| Completed | Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Gliob NCT01648348 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent NCT01378481 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | 3T MRI Biomarkers of Glioma Treatment Response NCT01996527 | Vanderbilt-Ingram Cancer Center | EARLY_Phase 1 |
| Terminated | Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme NCT01575275 | Michael Vogelbaum, MD, PhD | Phase 2 |
| Terminated | Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas NCT01478321 | Northwestern University | Phase 2 |
| Terminated | Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients Wi NCT02967380 | University of Southern California | N/A |
| Terminated | RO4929097 in Treating Patients With Recurrent Invasive Gliomas NCT01269411 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma NCT01189240 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Yoga Therapy in Treating Patients With Malignant Brain Tumors NCT01234805 | Wake Forest University Health Sciences | N/A |
| Completed | Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases NCT01234740 | City of Hope Medical Center | Phase 1 |
| Terminated | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressiv NCT01122901 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Col NCT01172964 | City of Hope Medical Center | Phase 1 |
| Completed | Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With NCT01165632 | Mayo Clinic | EARLY_Phase 1 |
| Terminated | Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors NCT01148966 | University of Washington | Phase 1 |
| Terminated | Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma NCT01103375 | Wake Forest University Health Sciences | Phase 1 |
| Completed | RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma NCT01119599 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors NCT01131234 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma NCT00979862 | National Cancer Institute (NCI) | Phase 1 |
| Completed | GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery NCT00980343 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma NCT01051557 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme NCT01122888 | National Cancer Institute (NCI) | Phase 1 |
| Completed | MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme NCT00902577 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multifo NCT00731731 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma NCT00823797 | University of Washington | Phase 2 |
| Completed | Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Gliobl NCT00650923 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme NCT00641706 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma NCT00662506 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme NCT00540722 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sunitinib in Treating Patients With Recurrent Malignant Gliomas NCT00499473 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pazopanib in Treating Patients With Recurrent Glioblastoma NCT00459381 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma NCT00423735 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme NCT00445588 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma NCT00379080 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide NCT00369590 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multi NCT00316849 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastom NCT00335764 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblasto NCT00305864 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme NCT00305656 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas NCT00268385 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme NCT00238303 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergo NCT00110032 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma NCT00112736 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multif NCT00085254 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multifor NCT00112866 | National Cancer Institute (NCI) | Phase 2 |
| Completed | FR901228 in Treating Patients With Recurrent High-Grade Gliomas NCT00085540 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma NCT00093613 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Und NCT00075491 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme NCT00058097 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other B NCT00039494 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma NCT00045565 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas NCT00045708 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multifo NCT00049387 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multifo NCT02227901 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma NCT00045110 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme NCT00052208 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagn NCT00430079 | National Cancer Institute (NCI) | N/A |
| Completed | CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme NCT00016328 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Bortezomib in Treating Patients With Recurrent Glioma NCT00006773 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme NCT00014170 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme NCT00005856 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM NCT00004146 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme NCT00004262 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gl NCT02055196 | City of Hope Medical Center | Phase 1 |